By using this model, we confirmed that RFH could significantly enhance the therapeutic effect of HSV-TK/GCV on hepatic tumors, as demonstrated by decreased cancer cell viability, reduced bioluminescent signal intensities, and decreased tumor volumes in the group treated with HSV-TK gene therapy and RFH, in comparison to RFH or gene therapy alone. This evidence concerns the gene TKT and cancer.